Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 322

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 322
---
 of the Company's existing contingent consideration liabilities. These changes were a result of updates made to certain inputs and assumptions impacting the probability-weighted expected cash flows, principally the probability of success of the underlying programs and the discount rate utilized to determine the present value of future payments to be made, partially offset by the termination of a license agreement with an academic institution that included an embedded derivative during both years ended December 31, 2024 and 2023. As of December 31, 2024 and 2023, the remaining contingent consideration was recorded as a non-current liability on the Company's consolidated balance sheets.The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, net and accounts payable approximated fair value because of the immediate or short-term maturity of these financial instruments. For fair value information related to the Company’s debt facilities, please read Note 13, Indebtedness.

6. CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIESThe following table summarizes the Company’s financial assets with maturities of less than 90 days from the date of purchase included in cash equivalents in the consolidated balance sheets for each of the periods indicated: 

        As of December 31,

        2024

        2023

        (in thousands)

        Money market funds
         
        $
        455,535

        $
        63,919

        Commercial paper

        —

        53,680

        Total
         
        $
        455,535

        $
        117,599

       It is the Company’s policy to mitigate credit risk in its financial assets by maintaining a well-diversified portfolio that limits the amount of exposure as to maturity and investment type. The weighted-average maturity of the Company's available-for-sale securities was approximately eleven and five months as of December 31, 2024 and 2023, respectively. All of the Company's non-current investments as of December 31, 2024 had maturities between one and two years. The following tables summarize the Company’s cash, cash equivalents, short-term investments and non-current investments for each of the periods indicated: 

F-22

        As of December 31, 2024

        Amortized Cost

        Gross Unrealized Gains

        Gross Unrealized Losses

        Fair MarketValue

        (in thousands)

        Cash and money market funds
         
        $